{{Rsnum
|rsid=1373494
|Chromosome=4
|position=33746904
|Orientation=plus
|GMAF=0.264
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;C)
|geno3=(C;C)
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;C)
| geno3=(C;C)
| CEU | 78.8 | 19.5 | 1.8
| HCB | 51.1 | 38.0 | 10.9
| JPT | 46.9 | 43.4 | 9.7
| YRI | 27.2 | 44.9 | 27.9
| ASW | 47.4 | 43.9 | 8.8
| CHB | 51.1 | 38.0 | 10.9
| CHD | 49.1 | 40.7 | 10.2
| GIH | 70.3 | 25.7 | 4.0
| LWK | 30.9 | 46.4 | 22.7
| MEX | 63.2 | 36.8 | 0.0
| MKK | 36.5 | 46.8 | 16.7
| TSI | 81.4 | 16.7 | 2.0
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs1373494
|Name_s=
|Gene_s=-
|Feature=
|Evidence=PubMed ID:19176441
|Annotation=This variant is associated with end-of-induction minimal risidual disease (MRD) in childhood acute lymphoblastic leukemia (ALL) from 2 independent cohorts (GWAS result). Risk Allele: C, MAF= 0.15, combined P value= 2.45E-04. It is also associated with etoposide clearance.
|Drugs=etoposide
|Drug Classes=
|Diseases=Neoplasm, Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma
|Curation Level=Curated
|PharmGKB Accession ID=PA162470216
}}

{{PMID|18205893|OA=1
}} Study of regions of extended homozygosity provides a powerful method to explore haplotype structure of human populations.

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs1373494
|overall_frequency_n=34
|overall_frequency_d=128
|overall_frequency=0.265625
|n_genomes=26
|n_genomes_annotated=0
|n_haplomes=30
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}